Cubist Systematic Strategies LLC Purchases Shares of 287,231 Quanterix Corporation $QTRX

Key Points

• Cubist Systematic Strategies LLC purchased 287,231 shares of Quanterix Corporation, valued at approximately $1.87 million, increasing their ownership to about 0.74% of the company.
• Director David R. Walt acquired 123,990 shares at an average price of $6.14 each, raising his total ownership to 1,866,933 shares, valued at around $11.46 million.
• Quanterix reported a loss of ($0.47) earnings per share for the last quarter, missing analyst estimates, with revenue of $24.48 million compared to expectations of $29.73 million.

Cubist Systematic Strategies LLC bought a new position in Quanterix Corporation (NASDAQ:QTRX - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 287,231 shares of the company's stock, valued at approximately $1,870,000. Cubist Systematic Strategies LLC owned about 0.74% of Quanterix as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC bought a new position in Quanterix in the 1st quarter worth about $98,000. Two Sigma Investments LP bought a new position in Quanterix in the 4th quarter worth about $606,000. Price T Rowe Associates Inc. MD increased its stake in Quanterix by 18.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 33,878 shares of the company's stock worth $361,000 after acquiring an additional 5,385 shares during the last quarter. Jane Street Group LLC increased its stake in Quanterix by 18.1% in the 4th quarter. Jane Street Group LLC now owns 55,947 shares of the company's stock worth $595,000 after acquiring an additional 8,578 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its stake in Quanterix by 46.2% in the 1st quarter. Envestnet Asset Management Inc. now owns 500,398 shares of the company's stock worth $3,258,000 after acquiring an additional 158,134 shares during the last quarter. 86.48% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Canaccord Genuity Group restated a "hold" rating and issued a $5.00 target price (down from $12.00) on shares of Quanterix in a research note on Monday, August 11th. Wall Street Zen cut Quanterix from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. One research analyst has rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $11.75.

Quanterix Trading Up 0.4%

Shares of QTRX traded up $0.02 during midday trading on Friday, reaching $4.81. The stock had a trading volume of 505,678 shares, compared to its average volume of 671,313. The company's 50-day moving average is $5.21 and its 200 day moving average is $5.75. Quanterix Corporation has a 12-month low of $4.05 and a 12-month high of $15.85. The company has a market capitalization of $223.52 million, a price-to-earnings ratio of -2.64 and a beta of 1.03.

Quanterix (NASDAQ:QTRX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.06). The firm had revenue of $24.48 million during the quarter, compared to analysts' expectations of $29.73 million. Quanterix had a negative return on equity of 18.41% and a negative net margin of 56.04%. Quanterix has set its FY 2025 guidance at EPS. Research analysts forecast that Quanterix Corporation will post -0.98 EPS for the current fiscal year.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.